Document Detail

Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome.
MedLine Citation:
PMID:  8287867     Owner:  NLM     Status:  MEDLINE    
Although early reperfusion of cardiac tissue is now considered to be the only intervention capable of restoring the various cellular functions altered by ischaemia and preventing progression towards necrosis of myocardial cells, reperfusion is frequently accompanied by various manifestations grouped under the heading of reperfusion syndrome or reperfusion injury. Functional recovery is therefore not immediate, but usually appears after a certain delay following a period of contractile dysfunction (myocardial stunning) lasting for several hours or even days after the start of reperfusion. Characteristic reperfusion-induced arrhythmias are also observed. The cellular mechanisms underlying the reperfusion syndrome may involve cellular calcium overload, over-production of oxygen-derived free radicals, acidosis and/or development of an inflammatory reaction. Numerous pharmacological studies have been conducted over several years designed to limit such reperfusion injury and, consequently, prevent stunning and/or reperfusion-induced arrhythmias. A number of experimental studies in this field have demonstrated that trimetazidine exerts direct anti-ischaemic effects, limiting calcium accumulation and acidosis, inflammation and oxygen-derived free radical production following reperfusion. This agent therefore appears to be particularly promising clinically in the treatment of reperfusion lesions, for example in combination with thrombolysis during the acute phase of myocardial infarction.
J de Leiris; F Boucher
Related Documents :
8156637 - Activation of cardiac vagal afferents in ischemia and reperfusion. prostaglandins versu...
16508397 - Isoflurane produces sustained cardiac protection after ischemia-reperfusion injury in m...
19162037 - Cb(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/...
8944817 - The effect of coenzyme q10 on infarct size in a rabbit model of ischemia/reperfusion.
2298827 - Astrocytic acidosis in hyperglycemic and complete ischemia.
15966917 - Ischemia-driven target vessel revascularization after-primary percutaneous coronary int...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European heart journal     Volume:  14 Suppl G     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-02-24     Completed Date:  1994-02-24     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  34-40     Citation Subset:  IM    
Groupe de Recherche sur la Physiopathologie Cellulaire Cardiaque Université Joseph Fourier, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcium / metabolism
Energy Metabolism
Free Radicals
Myocardial Infarction / drug therapy
Myocardial Reperfusion Injury / drug therapy*,  prevention & control
Myocardium / metabolism
Reactive Oxygen Species
Thrombolytic Therapy
Trimetazidine / therapeutic use*
Reg. No./Substance:
0/Free Radicals; 0/Reactive Oxygen Species; 5011-34-7/Trimetazidine; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The mechanism of myocyte death in ischaemia.
Next Document:  Thrombolysis: state of the art.